First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer — CC-OV01  

Uterine Cervical Neoplasms Clinical Trial

Official title: A First-in-human Phase I Two-stage Clinical Trial for Intratumoral Injection of Recombinant Oncolytic Type II Herpes Simplex Virus (BS-006) in Patients With Recurrent Cervical Cancer

Status Recruiting

Clinical Trial Summary

This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.

Clinical Trial Description

This trial includes accelerated dose-escalation stage and dose-expansion stage. An engineered modification oncolytic viruses, BS-006, derived from type II herpes simplex virus strain are planed to be injected into the tumor every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. In dose-escalation stage, there are three dose levels (1 million, 10 millions, 100 millions 50 % cell culture infectious dose (CCID50)/ml) . Treatment dose will escalate to next higher level if no dose limiting toxicity happens for one time of injection in 3 subjects. Maximal tolerable dose is defined as the highest dose with no more than one dose limiting toxicity and is recommended for dose expansion stage. In dose-expansion stage, 15 subjects will be enrolled. BS-006 viruses will be injected into proper tumor lesions every 2 weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. Radiology assessment will repeat every 6 weeks. Dose interruption, not reduction, is permitted in this stage. ;

Related Conditions & MeSH terms

• Uterine Cervical Neoplasms

• NCT number: NCT05393440
• Study type: Interventional
• Source: Zhongnan Hospital
• Contact: Shaoxing Sun, M. D.
• Phone: +08613871286154
• Email: sunshaoxing@whu.edu.cn
• Status: Recruiting
• Phase: Phase 1
• Start date: September 16, 2022
• Completion date: July 1, 2024